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Perivascular spaces (PVSs) are tiny cavities of cerebrospi-nal fluid that surround arterioles that penetrate the brain 
parenchyma.1 They are most frequently found in the inferior 
basal ganglia (BG), centrum semiovale (CS), and midbrain.2 
Although it is normal to have a few visible PVSs on neuro-
imaging,3 an increased burden of BG and CS-PVSs has been 
associated with increasing age,4–7 hypertension,4–6,8 renal 
impairment,9 white matter hyperintensity (WMH),4–6,8,10 and 
lacunes.4,6,8,10 BG-PVSs in addition have also been associ-
ated with male sex,6 mean systolic and diastolic blood pres-
sure,8,11 deep or infratentorial cerebral microbleeds,7,8 and also 
stroke caused by small vessel occlusion.10 BG-PVSs have 
been considered a marker of hypertensive arteriopathy sec-
ondary to endothelial dysfunction7,8 and have recently been 
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proposed as 1 of the 4 components of the Total Small Vessel 
Disease (SVD) Score.12 In contrast, CS-PVSs have been asso-
ciated with lobar microbleeds in healthy adults and in those 
with cognitive impairment.5,8 A high burden of CS-PVSs has 
also been noted in patients with cerebral amyloid angiopathy 
(CAA).7,13 It has, therefore, been hypothesized that in con-
trast to BG-PVSs, CS-PVSs may be a neuroimaging marker 
of CAA by representing fluid and metabolic waste clearance 
dysfunction because of vascular amyloid deposition.7,8,14
Although PVSs have shown potential as an imaging bio-
marker of hypertensive angiopathy and CAA, the long-term 
prognostic implications of PVSs among patients with tran-
sient ischemic attack (TIA) and ischemic stroke have yet to 
be determined. Ethnic differences in PVS are also uncertain. 
To address these unanswered questions, we performed 2 large 
prospective studies, consisting of >2000 whites and Chinese 
with TIA/ischemic stroke from 2 independent cohorts to 
determine the associations of PVSs with ethnicity, vascular 
risk factors, other neuroimaging markers of SVD, and long-
term risks of stroke and death.
Methods
We prospectively studied patients with TIA/ischemic stroke from 2 
cohorts: the OXVASC (Oxford Vascular) Study and the University 
of Hong Kong (HKU). In brief, OXVASC is an ongoing population-
based study of all acute vascular events occurring within a popula-
tion of all 92 728 individuals, irrespective of age, who are registered 
with 100 general practitioners in 9 general practices of Oxfordshire, 
United Kingdom.15 The analysis herein includes 1080 consecutive 
cases of TIA/ischemic stroke recruited from November 1, 2004, to 
September 30, 2014, who had a cerebral magnetic resonance imag-
ing (MRI). The imaging protocol of OXVASC has been described 
in detail elsewhere.16 Briefly, from April 1, 2002, to March 31, 2010 
(phase 1), MRI and magnetic resonance angiography were done 
in selected patients when clinically indicated. From April 1, 2010, 
onward (phase 2), brain MRI and magnetic resonance angiography 
of intra- and extracranial vessels became the first-line imaging meth-
ods.16 A further 1076 consecutive patients who were predominantly 
Chinese with a diagnosis of acute ischemic stroke who received an 
MRI scan and magnetic resonance angiography of the intra- and 
extracranial blood vessels at the HKU MRI Unit were recruited dur-
ing March 1, 2008, to September 30, 2014.
We collected demographic data, atherosclerotic risk factors, and 
details of hospitalization of index event during face-to-face interview 
and cross-referenced these with primary care records and hospital 
records in both cohorts. Cause of TIA/ischemic stroke was classi-
fied according to the modified Trial of ORG 10172 in Acute Stroke 
Treatment (TOAST) criteria.17
Details of scan parameters are documented in Table I in the online-
only Data Supplement. Two neuroradiologists (H.K.F.M. and W.K.) 
supervised the interpretation of the MRI images. PVSs were defined as 
small (<3 mm) punctate (if perpendicular to the plane of scan) or lin-
ear (if longitudinal to the plane of scan) hyperintensities on T2 images 
in the BG or CS based on a previously validated scale.18 In patients 
with asymmetrical number of PVSs, the side with the higher number of 
PVSs was counted.18 Burden of PVSs was then stratified into 3 groups: 
<11, 11 to 20, and >20 (frequent–severe).18 Definitions of subcortical 
and periventricular WMH, microbleeds, and lacunes are provided in 
the online-only Data Supplement. The intrarater κ for burden of PVS 
(<11, 11–20, and >20) was 0.86 (BG) and 0.84 (CS) in OXVASC and 
0.86 (BG) and 0.72 (CS) in HKU (50 scans in each center). Seventy-
five MRI scans from HKU were cross-interpreted by investigators in 
OXVASC with an interrater κ of 0.64 for both BG and CS-PVSs.
All patients in OXVASC were followed up regularly by a research 
nurse or physician after 1, 3, 6, 12, 24, 60, and 120 months after 
the index event. Patients recruited from HKU were followed up by 
a clinician every 3 to 6 months, or more frequently if clinically indi-
cated. All patients were assessed for recurrent stroke (ischemic and 
hemorrhagic) and death (vascular and nonvascular; see definitions in 
the online-only Data Supplement). Where needed, details of clinical 
outcomes were supplemented by electronic or paper medical records 
from individual primary care practices, hospitals, and the Deaths 
General Register Office.
Patients gave written informed consent after an event or assent 
was obtained from relatives for patients who were unable to provide 
consent. Both cohorts were approved by the local research ethics 
committee.
Statistical Analysis
We compared differences in baseline and imaging characteristics in 
the OXVASC and HKU cohorts using Student t test for continuous 
variables and χ2 test for categorical variables. The predictors of >20 
BG and CS-PVSs were determined using a logistic regression model 
adjusted for center and MRI scanner strength. Variables including 
age, male sex, vascular risk factors (hypertension, hyperlipidaemia, 
diabetes mellitus, smoking, and atrial fibrillation), renal impairment 
(defined as glomerular filtration rate <60 mL/min/1.73 m2, as mea-
sured by the Modification of Diet in Renal Disease Study equation19), 
periventricular and subcortical WMH, deep and lobar microbleed 
number and lacunes were entered into a univariate analysis model. All 
variables were subsequently entered into a multivariate analysis model 
to determine the independent predictors of >20 BG and CS-PVSs. The 
multivariate model to determine the independent predictors of >20 
BG-PVSs was also adjusted for CS-PVSs and vice versa.
In a logistic regression model, we determined the odds of a TIA/
ischemic stroke because of SVD with increasing burden of BG and 
CS-PVSs, adjusted for age, sex, vascular risk factors, center, and MRI 
scanner strength.
We used Kaplan–Meier survival analysis to calculate the 5-year 
risk of a recurrent stroke (ischemic and hemorrhagic) and all-cause 
mortality, censored at death or March 31, 2015, according to the bur-
den of PVSs. We also determined, by Cox regression analysis, the 
unadjusted and adjusted (for age, sex, vascular risk factors, center, 
and MRI scanner strength) risks of recurrent stroke (ischemic and 
hemorrhagic), mortality (vascular and nonvascular) in patients with 
11 to 20 and >20 BG and CS-PVSs compared with <11 PVSs as 
reference. Finally, we performed a stratified analysis to determine 
whether the prognosis of PVSs differed in patients with no or mild 
versus moderate or severe periventricular and subcortical WMH.
All analyses were done with SPSS version 20.
Role of the Funding Source
The funding source had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The correspond-
ing authors had full access to all the data in the study and had the final 
responsibility for the decision to submit for publication.
Results
The 2 study populations contributed a total of 2156 patients. 
After excluding 154 patients with incomplete clinical or imag-
ing data, 2002 (OXVASC n=1028, 542 TIA, 486 ischemic 
stroke; HKU n=974, all ischemic stroke) were included in the 
final analysis. Baseline clinical and imaging characteristics of 
patients are shown in Table 1. Proportion of patients according 
to TOAST classification is shown in Table II in the online-
only Data Supplement. HKU patients had a higher proportion 
of men (P=0.001) and were more likely to have hypertension 
and diabetes mellitus (P<0.0001), whereas OXVASC patients 
were more likely to have hyperlipidaemia or a history of 
smoking (P<0.0001; Table 1).
Patients from OXVASC had a higher burden of >20 BG 
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10.4%; P<0.0001) compared with those from HKU (Table 1). 
These differences in PVS burden remained, despite strati-
fication of individuals into stroke subtypes (Table III in the 
online-only Data Supplement). OXVASC patients also had 
more severe periventricular WMH (P<0.0001; Table 1). In 
contrast, those from HKU had a greater burden of subcorti-
cal WMH (P<0.0001) and microbleeds (P<0.0001; Table 1). 
These differences remained in analyses confined to patients 
who received an MRI with a 3T scanner (Table IV in the 
online-only Data Supplement). However, within OXVASC, 
patients who received a 3T MRI (n=446) had a greater bur-
den of >20 BG-PVSs (25.8% versus 19.8%; P=0.022) and 
CS-PVSs (55.6% versus 38.3%; P<0.0001) compared with 
patients who received a 1.5T MRI (n=582).
Burden of BG and CS-PVSs increased with age, baseline 
history of hypertension, atrial fibrillation, and renal impairment 
(P<0.05; Table V in the online-only Data Supplement). Burden 
of BG and CS-PVSs was also greater in patients with lacunes 
and severe WMH (P<0.05; Table V in the online-only Data 
Supplement). In a multivariate analysis, >20 BG or CS-PVSs 
were associated with increasing age (multivariate adjusted odds 
ratio [OR], BG: 1.05; 95% confidence interval [CI], 1.03–1.07; 
P<0.0001; CS: OR, 1.01; 95% CI, 1.00–1.03; P=0.020) and sub-
cortical WMH (BG: OR, 1.44; 95% CI, 1.20–1.72; P<0.0001; 
CS: OR, 1.28; 95% CI, 1.09–1.50; P=0.003). More than 20 
BG-PVSs were also associated with atrial fibrillation (OR, 
1.58; 95% CI, 1.10–2.29; P=0.014) and periventricular WMH 
(OR, 2.01; 95% CI, 1.66–2.44; P<0.0001; Table 2; Table VI in 
the online-only Data Supplement). Although underlying signifi-
cant (>50%) large artery atherosclerosis was not related to >20 
BG-PVSs (multivariate adjusted OR, 1.10; 95% CI, 0.77–1.56; 
P=0.61), an independent association between >20 CS-PVSs 
with significant large artery disease was noted (OR, 1.44; 95% 
CI 1.07–1.93; P=0.015). Whites, as compared with Chinese, 
were at increased odds of >20 BG (multivariate adjusted OR, 
2.09; 95% CI, 1.35–3.22; P=0.001) and CS-PVSs (OR, 8.82; 
95% CI, 6.25–12.46; P<0.0001). These ORs remained similar 
after additional adjustment of MRI magnet strength (BG: OR, 
2.50; 95% CI, 1.56–4.02; P=0.0002; CS: OR, 11.93; 95% CI, 
8.15–17.47; P<0.0001).
A 26.8% of the study population was classified to have TIA/
ischemic stroke because of SVD (Table II in the online-only 






  Mean age, y, SD 68 (14) 69 (12) 0.25
  Men, % 538 (52.3) 583 (59.9) 0.001
  Hypertension, % 563 (54.8) 640 (65.7) <0.0001
  Diabetes mellitus, % 136 (13.2) 275 (28.2) <0.0001
  Hyperlipidaemia, % 381 (37.1) 249 (25.6) <0.0001
  Ever smokers, % 521 (50.7) 291 (29.9) <0.0001
  Atrial fibrillation, % 160 (15.6) 128 (13.1) 0.12
  Prior TIA/stroke, % 187 (18.2) 154 (15.8) 0.16
Imaging characteristics
  Magnet strength, T 1.5T n=582, 3T n=446 3T n=974  
  No. with DWI positive 
lesion, %
233 (22.7) 759 (77.9) <0.0001
  No. with basal 
ganglia PVSs, %
   
   <11 (%) 527 (51.3) 659 (67.7) <0.0001
   11–20 (%) 271 (26.4) 246 (25.3)  
   >20 (%) 230 (22.4) 69 (7.1)  
  No. with centrum 
semiovale PVSs, %
   
   <11 226 (22.0) 410 (42.1) <0.0001
   11–20 331 (32.2) 463 (47.5)  
   >20 471 (45.8) 101 (10.4)  
  No. with lacunes, % 182 (17.7) 430 (44.1) <0.0001
  No. with  
microbleeds, %
156 (15.2) 441 (45.3) <0.0001
   1 microbleed 79 (7.7) 179 (18.4)  
   2–4 microbleeds 44 (4.3) 145 (14.9)  
   ≥5 microbleeds 39 (3.8) 117 (12.0)  
  No. with 
periventricular  
WMH, %
   
   Grade 1 386 (37.5) 213 (21.9) <0.0001
   Grade 2 201 (19.6) 75 (7.7)  
   Grade 3 96 (9.3) 30 (3.1)  
No. with subcortical WMH, %
   Grade 1 338 (32.9) 475 (48.8) <0.0001
   Grade 2 177 (17.2) 278 (28.5)  
   Grade 3 117 (11.4) 155 (15.9)  
Outcome
  Mean follow-up  
time, mo
45±26 37±19  
  Patient-years  
follow-up
3884 3040  
  Recurrent stroke, % 90 (8.8) 109 (11.2) 0.069
  Ischemic stroke, % 81 (7.9) 89 (9.1) 0.31
   Fatal, % 6 (7.4) 12 (13.4) 0.13
  Intracerebral 
hemorrhage, %
9 (0.9) 20 (2.1) 0.027
   Fatal, % 3 (33.3) 6 (30.0) 0.28
  Deaths, % 142 (13.8) 124 (12.7) 0.48
   Vascular deaths, % 35 (24.6) 57 (46.0) 0.009
DWI indicates diffusion weighted imaging; HKU, University of Hong Kong; 
OXVASC, Oxford Vascular Study; PVS, perivascular space; TIA, transient 
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Data Supplement). These patients were associated with a 
higher BG and CS-PVS burden (multivariate adjusted OR 
compared with <11 PVSs, 11–20 BG-PVSs: OR, 2.44; 95% 
CI, 1.45–4.10; >20 BG-PVSs: OR, 2.82; 95% CI, 1.60–4.97; 
P=0.0002; 11–20 CS-PVSs: OR, 2.54; 95% CI, 1.32–4.88; 
>20 CS-PVSs: OR, 4.20; 95% CI, 2.19–8.06; P<0.0001).
After a mean follow-up of 42±23 months (OXVASC 45±26 
months, HKU 37±19 months, 6924 patient-years of follow-
up), 199 recurrent strokes occurred (85.4% ischemic; Table 1). 
Two hundred sixty-six patients died, 34.6% of which were vas-
cular deaths. The 5-year risk of recurrent ischemic stroke and 
intracerebral hemorrhage (ICH) in patients with <11, 11 to 20, 
and >20 BG-PVSs was 8.5%, 11.5%, and 19.3% (log-rank test: 
P<0.0001) and 1.6%, 2.3%, and 3.7%, respectively (P=0.038; 
Figure 1). An increasing burden of BG-PVSs was also associ-
ated with a higher all-cause mortality (P<0.0001; Figure 1). In 
contrast, burden of CS-PVSs was not associated with recur-
rent ischemic stroke (P=0.76), intracerebral hemorrhage (ICH; 
P=0.96), or all-cause mortality (P=0.33; Figure 2).
On Cox regression analysis, strong univariate association 
between increasing burden of BG-PVSs with all-cause mor-
tality was noted (P<0.0001), but this association disappeared 
after adjustment for age and sex (P=0.058) and on multivari-
ate adjustment (P=0.16; Table VII in the online-only Data 
Supplement). In contrast, the strong univariate associations 
between increasing burden of BG-PVSs with recurrent isch-
emic stroke persisted with multivariate adjustment (hazard 
ratio compared with <11 BG-PVSs, 11–20: HR, 1.15; 95% 
CI, 0.78–1.68; >20: HR, 1.82; 95% CI, 1.18–2.80; P=0.011; 
Table 3;  Table VIII in the online-only Data Supplement). 
BG-PVS burden was not independently associated with ICH 
(P=0.10; Table 3). An increasing burden of CS-PVSs was not 
related to ischemic stroke (P=0.42), ICH (P=0.69), or mor-
tality (P=0.072; Table 3; Table VII in the online-only Data 
Supplement). When patients were stratified by MRI scan-
ner in OXVASC, the prognostic value of BG and CS-PVSs 
remained similar for prediction of recurrent stroke (BG-PVS: 
P=0.15; CS-PVS: P=0.45; Table IX in the online-only Data 
Supplement). Similarly, no heterogeneity was observed when 
analyses for risk of recurrent stroke were stratified by patients 
with no or mild versus moderate–severe WMH (BG-PVS: 
P=0.92; CS-PVS: P=0.076; Table X in the online-only Data 
Supplement). In an unadjusted model, burden of BG-PVSs, 
microbleeds, periventricular WMH, subcortical WMH, 
and presence of lacunes were all associated with recurrent 
ischemic stroke (P<0.05; Table XI in the online-only Data 
Supplement). Forward stepwise multivariate Cox regres-
sion model adjusting for all neuroimaging markers of SVD 
revealed that burden of BG-PVSs (P=0.001) and microbleeds 
(P=0.001) as independent predictors of recurrent ischemic 
stroke (Table XI in the online-only Data Supplement).
Discussion
Our study has combined the 2 largest current cohorts from 
the west and the east of the clinical implications of BG and 
CS-PVSs in patients with TIA/ischemic stroke and is the first 
to determine the ethnic differences in prevalence. In our study, 
PVSs were coded according to a validated rating scale,18 with 
excellent intrarater variability and good interrater variability 
when scans were cross-interpreted between the 2 centers. Our 
study is also the first to determine the long-term prognostic 
implications of PVSs in patients with TIA/ischemic stroke.
Our results support those from previous studies that BG and 
CS-PVSs are both markers of hypertensive angiopathy.6,8,14 We 
too found that PVSs were associated with age4–6 and WMH.5,6 
Concordant with previous studies,4–8,10 we also found that 
compared with CS-PVSs, BG-PVSs were a stronger marker 
of hypertensive angiopathy, with greater associations with 
periventricular and subcortical WMH and that BG-PVSs were 
more strongly associated with TIA/ischemic stroke because of 
SVD. Although previous studies have also noted significant 
associations of BG-PVS with deep microbleeds,7,8 this finding 
did not reach statistical significance in our cohorts (P=0.063).
Table 2. Clinical Correlates of >20 Perivascular Spaces
 
Multivariate Adjusted*
OR (95% CI) P Value
Basal ganglia
  Age, y 1.05 (1.03–1.07) <0.0001
  Male sex 1.17 (0.86–1.59) 0.33
  Hypertension 0.98 (0.70–1.37) 0.91
  Diabetes mellitus 1.09 (0.74–1.62) 0.67
  Hyperlipidaemia 0.81 (0.58–1.13) 0.22
  Ever smoker 0.86 (0.62–1.19) 0.37
  Atrial fibrillation 1.58 (1.10–2.29) 0.014
  GFR<60 mL/min/1.73m2 0.81 (0.57–1.15) 0.24
  Periventricular WMH 2.01 (1.66–2.44) <0.0001
  Subcortical WMH 1.44 (1.20–1.72) <0.0001
  No. with deep microbleed 1.05 (1–1.10) 0.063
  No. with lobar microbleed 1.00 (0.98–1.02) 0.84
  Lacunes 1.18 (0.84–1.65) 0.34
Centrum semiovale
  Age, y 1.01 (1–1.03) 0.020
  Male sex 0.88 (0.69–1.12) 0.29
  Hypertension 1.13 (0.87–1.48) 0.36
  Diabetes mellitus 1.15 (0.83–1.60) 0.39
  Hyperlipidaemia 0.94 (0.72–1.23) 0.67
  Ever smoker 0.91 (0.70–1.17) 0.45
  Atrial fibrillation 0.85 (0.61–1.19) 0.34
  GFR<60 mL/min/1.73m2 0.87 (0.64–1.18) 0.37
  Periventricular WMH 0.90 (0.76–1.08) 0.26
  Subcortical WMH 1.28 (1.09–1.50) 0.003
  No. with deep microbleed 0.95 (0.86–1.04) 0.25
  No. with lobar microbleed 0.98 (0.94–1.02) 0.26
  Lacunes 1.26 (0.95–1.69) 0.11
CI indicates confidence interval; GFR, glomerular filtration rate; OR, odds 
ratio; and WMH, white matter hyperintensity.
*Also adjusted for center, MRI scanner strength, CS-PVSs for prediction of 
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The stronger association of BG-PVSs with hypertensive 
angiopathy was also reflected in our long-term follow-up data. 
Compared with <11 PVSs, TIA/ischemic stroke patients with 
>20 BG-PVSs were at 1.8-fold increased risk of recurrent 
ischemic stroke on multivariate analysis. There was a trend 
toward patients with increasing burden of BG-PVSs being 
Figure 2. Risk of (A) recurrent stroke, (B) recurrent ischemic stroke, (C) intracerebral hemorrhage, and (D) all-cause mortality among tran-
sient ischemic attack/ischemic stroke patients with increasing centrum semiovale perivascular space burden. CS-PVS indicates centrum 
semiovale perivascular spaces.
Figure 1. Risk of (A) recurrent stroke, (B) recurrent ischemic stroke, (C) intracerebral hemorrhage, and (D) all-cause mortality among tran-
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similarly at increased risk of subsequent ICH and mortality. 
Furthermore, we were able to demonstrate that the prognostic 
implications of BG-PVSs were independent of other neuroim-
aging markers of SVD.
In contrast, although previous studies have revealed an 
association of CS-PVSs with lobar microbleeds5,8 and CAA,7 
suggesting that CS-PVSs may be an imaging biomarker of 
CAA,5,7,8 CS-PVSs were not associated with lobar microbleeds 
nor adverse clinical events including ICH in our cohorts. It 
should be noted, however, that studies that have ascertained 
the relationship of CS-PVSs with lobar microbleeds were 
based on either healthy adults or subjects recruited from a 
memory clinic,5,8 with an expected lower prevalence of vascu-
lar risk factors and hence less severe imaging markers of SVD 
compared with patients in our study. It is widely accepted that 
PVSs may be difficult to identify in patients with extensive 
WMH.18 This is particularly the case for CS-PVSs that are 
often masked by subcortical WMHs. Indeed, in our high-risk 
cohort, where 36% of individuals had moderate–severe sub-
cortical WMH, the true prevalence of CS-PVSs would without 
doubt be underestimated.
Our results also demonstrate that significant ethnic differ-
ences in PVS prevalence exist. We showed a similar preva-
lence of >20 BG and CS-PVSs in OXVASC to a previous 
study of whites with TIA/ischemic stroke.4 In contrast, how-
ever, our study showed that Chinese with TIA/ischemic stroke 
had a much lower prevalence of PVSs. The prevalence of 
BG and CS-PVSs among Chinese with ischemic stroke has 
Table 3. Cox Regression Analyses of Recurrent Stroke With Increasing Burden of 
Perivascular Spaces Versus <11 Perivascular Spaces
No. of PVSs
HR (95% CI) Adjusted for Age, Sex, Vascular Risk Factors,* and MRI Scanner 
Strength†
11–20 >20 P Value
Basal ganglia PVSs
  Recurrent stroke    
   OXVASC 1.11 (0.62–1.97) 1.90 (1.11–3.25) 0.021
   HKU 1.20 (0.77–1.87) 2.32 (1.29–4.15) 0.013
   Combined‡ 1.13 (0.79–1.61) 1.94 (1.31–2.89) 0.002
  Ischemic stroke    
   OXVASC 1.04 (0.56–1.92) 1.99 (1.13–3.49) 0.020
   HKU 1.30 (0.80–2.11) 1.94 (0.98–3.85) 0.056
   Combined‡ 1.15 (0.78–1.68) 1.82 (1.18–2.80) 0.011
  Intracerebral hemorrhage    
   OXVASC 1.03 (0.17–6.16) 0.95 (0.14–6.22) 0.95
   HKU 0.79 (0.24–2.58) 3.84 (1.20–12.29) 0.089
   Combined‡ 0.95 (0.37–2.46) 2.58 (0.97–6.89) 0.10
Centrum semiovale PVSs
  Recurrent stroke    
   OXVASC 0.83 (0.44–1.57) 1.30 (0.71–2.37) 0.21
   HKU 1.07 (0.73–1.58) 0.37 (0.15–0.94) 0.16
   Combined‡ 0.92 (0.66–1.28) 0.89 (0.60–1.33) 0.57
  Ischemic stroke    
   OXVASC 0.94 (0.49–1.82) 1.28 (0.68–2.41) 0.33
   HKU 1.12 (0.73–1.72) 0.28 (0.09–0.92) 0.18
   Combined‡ 0.96 (0.67–1.37) 0.83 (0.54–1.28) 0.42
  Intracerebral hemorrhage    
   OXVASC … 1.29 (0.19–8.69) 0.35
   HKU 0.86 (0.34–2.17) 0.75 (0.16–3.51) 0.67
   Combined‡ 0.69 (0.28–1.67) 1.36 (0.51–3.59) 0.69
CI indicates confidence interval; HKU, University of Hong Kong; HR, hazard ratio; MRI, magnetic resonance imaging; 
OXVASC, Oxford Vascular Study; and PVS, perivascular space.
*Hypertension, hyperlipidaemia, diabetes mellitus, atrial fibrillation, and smoking history.
†Compared with <11 PVSs as reference.




 http://ahajournals.org by on D
ecem
ber 17, 2020
1476  Stroke  June 2017
previously been reported.9,20 One study showed that 10.7% of 
subjects had >40 BG-PVSs,20 and in another, ≈40% of sub-
jects had >10 BG or CS-PVSs.9 These 2 studies, however, 
were purely based on patients with lacunar stroke subtype.9,20 
In a large cohort of neurologically healthy Japanese individu-
als, a low prevalence of >20 BG-PVS and CS-PVS of 2.5% 
and 22.6% was similarly noted.8 Such low prevalence of >20 
PVSs in the HKU cohort would have limited the statistical 
power when determining the clinical correlates of PVSs and 
attributed to some of the differences observed when compared 
with OXVASC. Atrial fibrillation was also noted to be sig-
nificantly associated with >20 BG-PVSs, whereas underly-
ing large artery disease was significantly associated with >20 
CS-PVSs in our cohorts. Further studies to confirm and to 
delineate the underlying mechanisms of our findings would 
be required. Finally, our findings are also limited by patients 
in OXVASC being scanned on 4 different scanners during the 
10-year study period. However, although this could have been 
a potential source of heterogeneity, the prognostic values for 
prediction of recurrent stroke with increasing burden of PVSs 
were similar across the 4 scanners, suggesting that the prog-
nostic value of PVSs is robust to variations in scanner type 
and sequences. PVS size, symmetry, or ventricular size was 
not studied in our cohorts. Hence, we were only able to study 
clinical and imaging correlates and prognostic implications 
according to PVS number18 but not its size or symmetry.
Our study has several clinical implications. First, in 2 large 
cohorts, our results confirm BG-PVSs as a marker of SVD, inde-
pendent of WMH. These results, therefore, justify the inclusion 
of BG-PVSs into the recently derived Total SVD Score.12 In the 
current version,12 patients with >11 BG-PVSs are given 1 point, 
as are patients with severe periventricular WMH or moderate–
severe subcortical WMH. Whether alternative cutoffs (eg, >20 
BG-PVSs) should be used instead in view of the relatively low 
prognostic value of patients with 11 to 20 BG-PVSs noted in 
our study would require further research. Second, although the 
burden of CS-PVSs may possibly have prognostic implications 
in healthy individuals or those seen in the Memory Clinic, the 
role of CS-PVSs as a prognostic imaging marker in the TIA/
ischemic stroke population seems to be limited.
In conclusion, in addition to identifying ethnic differences 
in frequency of PVSs, we found that BG-PVSs are markers of 
hypertensive angiopathy and predict risk of recurrent ischemic 
stroke in patients with TIA/ischemic stroke, independent of 
WMH. In contrast, the prognostic value of CS-PVSs in TIA/
ischemic stroke is limited.
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